[1] ETZERODT A,MOULIN M,DOKTOR T K,et al.Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer[J]. J Exp Med,2020, 217(4):e20191869. [2] LIANG R,YUNG M M H,HE F F,et al. The stress-inducible BCL2A1 is required for ovarian cancer metastatic progression in the peritoneal microenvironment[J]. Cancers (Basel),2021, 13(18):4577. [3] LU M M,GAO Q,WANG Y F,et al.LINC00511 promotes cervical cancer progression by regulating the miR-497-5p/MAPK1 axis[J]. Apoptosis,2022,27(11/12):800-811. [4] 张曦文. 双靶向uPAR和HER2串联CAR-T细胞治疗上皮性卵巢癌的实验研究[D]. 长春:吉林大学,2023. [5] JNEID B,BOCHNAKIAN A,HOFFMANN C,et al. Selective STING stimulation in dendritic cells primes antitumor T cell responses[J]. Sci Immunol,2023, 8(79):eabn6612. [6] KLICHINSKY M,RUELLA M,SHESTOVA O,et al.Human chimeric antigen receptor macrophages for cancer immunotherapy[J]. Nat Biotechnol,2020, 38(8):947-953. [7] WANG X D,FU J,JIANG C,et al.Specific and long-term luminescent monitoring of hydrogen peroxide in tumor metastasis[J]. Adv Mater,2023,35(20):e2210948. [8] LOUWE P A,FORBES S J,BÉNÉZECH C,et al. Cell origin and niche availability dictate the capacity of peritoneal macrophages to colonize the cavity and omentum[J]. Immunology,2022,166(4):458-474. [9] LENGEL H B,MASTROGIACOMO B,CONNOLLY J G,et al. Genomic mapping of metastatic organotropism in lung adenocarcinoma[J]. Cancer Cell,2023,41(5):970-985.e3. [10] HORACKOVA K,ZEMANKOVA P,NEHASIL P,et al.A comprehensive analysis of germline predisposition to early-onset ovarian cancer[J]. Sci Rep,2024, 14(1): 16183. [11] SHENOY G N,GREENE C J,BHATTA M,et al.Preclinical evaluation of cancer immune therapy using patient-derived tumor antigen-specific T cells in a novel xenograft platform[J]. Clin Transl Immunology,2021, 10(2):e1246. [12] VERDUN N,MARKS P.Secondary cancers after chimeric antigen receptor T-cell therapy[J]. N Engl J Med,2024,390(7):584-586. [13] AKTARY Z,RAYMOND J H,POUTEAUX M,et al. Derivation and use of cell lines from mouse models of melanoma[J]. J Invest Dermatol,2023,143(4):538-544.e2. [14] YI M,NIU M K,WU Y Z,et al.Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101:a novel immune cocktail therapy for non-inflamed tumors[J]. J Hematol Oncol,2022, 15(1):142. [15] JIA J F,ZENG M N,ZHU D H,et al.An amide alkaloid isolated from Ephedra sinica ameliorates OVA-induced allergic asthma by inhibiting mast cell activation and dendritic cell maturation[J]. Int J Mol Sci,2022, 23(21):13541. [16] CHEN F M,LI T L,ZHANG H J,et al.Acid-ionizable iron nanoadjuvant augments STING activation for personalized vaccination immunotherapy of cancer[J]. Adv Mater,2023,35(10):e2209910. [17] YAO Y,LIU C,WANG B J,et al.HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis[J]. Cancer Lett,2022,533:215595. [18] 林永芳,吴黎川,揭晓亮,等. 肿瘤细胞原位重编程为抗原呈递细胞的策略[J]. 广西医科大学学报,2024, 41(11):1491-1495. [19] SHAPIR ITAI Y,BARBOY O,SALOMON R,et al. Bispecific dendritic-T cell engager potentiates anti-tumor immunity[J]. Cell,2024,187(2):375-389.e18. |